Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 9Breast Neoplasms 5Uterine Cervical Neoplasms 4Gliosarcoma 4Glioma 4Glioblastoma 4Ganglioneuroblastoma 4Pancreatic Neoplasms 3Neuroblastoma 3Vaginal Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Lung Neoplasms 2Glioma, Subependymal 2Ependymoma 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma Of Esophagus 2Wilms Tumor 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thoracic Diseases 1

Interventions

Temozolomide 15Radiotherapy 11Everolimus 6Bevacizumab 6Irinotecan 5Cyclophosphamide 5ribociclib 4Radiation 4Panobinostat 4TIC10 compound 3Specimen Handling 3Re-Irradiation 3Etoposide 3Dasatinib 3pembrolizumab 2nimotuzumab 2abemaciclib 2Vorinostat 2Valproic Acid 2Topotecan 2Nivolumab 2Mebendazole 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2GDC-0084 2Erlotinib Hydrochloride 2Diphtheria-Tetanus Vaccine 2Cilengitide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × Congresses as Topic × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡